Q-omics provides the consensus-scored CTAGE9 profile across patient tissues and cancer cell-line models. CTAGE9 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, CTAGE9 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, CTAGE9 RNA expression shows 9,999 significant gene co-expression associations, with the highest sampling consensus in KIRC. Together, these results highlight SCLC, and KIRC as cancer lineages where CTAGE9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CTAGE9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CTAGE9 survival associations across molecular data types. CTAGE9 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CTAGE9 RNA expression–survival associations across cancer types. High CTAGE9 expression shows unfavorable associations in ACC, CHOL, UCEC and COAD, but favorable associations in SCLC and KIRP. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify SCLC as the clearest survival context for CTAGE9 RNA expression.
This table summarizes CTAGE9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CTAGE9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CTAGE9 shows higher tumor expression in KIRC, HNSC, UCEC, CHOL, LUAD and LIHC. The KIRC box plot shows higher CTAGE9 RNA expression in tumor versus normal tissue (log2 FC = +0.402, t-test p < 0.001).
This table shows molecular features associated with CTAGE9 in patient tissues and cancer cell lines. In patient samples, CTAGE9 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set. In cancer cell lines, CTAGE9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
